<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the expression of AML1/ETO9a isoform in the <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)-M2 patients </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Expressions of AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi> fusion gene and AML1/ETO9a isoform were detected by using reverse transcriptase-polymerase chain reaction (RT-PCR) in <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines and healthy subjects </plain></SENT>
<SENT sid="2" pm="."><plain>Karyotype was studied by R-banding technique </plain></SENT>
<SENT sid="3" pm="."><plain>RESULT: In 30 newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-M2 patients 15 were found to express AML1/ETO9a isoform, while the rest including 20 AML-M2CR, 18 other subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 5 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), 3 <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 3 <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines (NB4, KG-1, K562) and 5 healthy subjects were AML1/ETO9a negative </plain></SENT>
<SENT sid="4" pm="."><plain>Among the 15 AML/ETO9a isoform expressing cases, 13 were demonstrated t(8;21) translocation and AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi> expression </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Isoform AML1/ETO9a was correlated to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/M2, and it may promote the development of <z:hpo ids='HP_0001909'>leukemia</z:hpo> in combination with the AML1/<z:chebi fb="0" ids="27561">ETO</z:chebi> fusion gene </plain></SENT>
</text></document>